New ophthalmic manifestations of presumed rifabutin-related uveitis.
Rifabutin-related uveitis has been reported in AIDS patients who take a daily dose of 300 to 1800 mg of this drug. Presumed rifabutin-related uveitis is characterized by unilateral or bilateral anterior chamber inflammation with hypopyon accompanied by hyperemia, pain, photophobia, and vitritis. However, retinal manifestations or vitreous cytology of this entity have never been reported. This report describes a patient who had retinal vascular changes associated with uveitis while being treated with oral rifabutin. Fundus photographs and fluorescein angiograms documented resolved retinal vasculitis. Vitreous cytology of this case showed acute inflammatory cells. To the authors' knowledge, this is the first report of retinal vasculopathy in a patient with rifabutin-related uveitis and the first analysis of the vitreous cytologic aspects of this disease.
Arevalo
J F
JF
Department of Ophthalmology, Shiley Eye Center, University of California, a-San Diego, La Jolla 92093-0946, USA.
Russack
V
V
Freeman
W R
WR
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000328:Adult; D000867:Anterior Chamber / Q000473:pathology; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000627:therapeutic use; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control; D012164:Retinal Diseases / Q000139:chemically induced / Q000175:diagnosis; D017828:Rifabutin / Q000009:adverse effects* / Q000627:therapeutic use; D014606:Uveitis, Anterior / Q000139:chemically induced*; D014657:Vasculitis / Q000139:chemically induced / Q000175:diagnosis; D014822:Vitreous Body / Q000473:pathology
D000904:Antibiotics, Antitubercular; D017828:Rifabutin